J. Schein

发表

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants

C. Coleman, S. Kaatz, P. Lefebvre, 2014, Current medical research and opinion.

Prior myocardial infarction and presence of upper gastrointestinal conditions among patients with venous thromboembolism: prevalence, associated comorbidities and burden

M. Dibonaventura, J. LaMori, B. Bookhart, 2014, Journal of clinical pharmacy and therapeutics.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty

W. Olson, F. Vekeman, M. Duh, 2012, Journal of medical economics.

Risk factors associated with myocardial infarction in venous thromboembolism patients

S. Kaatz, P. Lefebvre, F. Laliberté, 2014, Current medical research and opinion.

International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation

W. Nelson, C. Damaraju, L. Fields, 2015, American Journal of Cardiovascular Drugs.

Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis.

S. Mody, W. Nelson, J. Menzin, 2016, Journal of comparative effectiveness research.

A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery

M. Duh, E. Nutescu, B. Bookhart, 2012 .

Warfarin prophylaxis in patients after total knee or hip arthroplasty – international normalized ratio patterns and venous thromboembolism

J. Schein, A. Fisher, B. Nordstrom, 2011, Current medical research and opinion.

Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP)

M. Dickson, S. Mody, J. Schein, 2010, Journal of medical economics.

Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events

E. Nutescu, B. Bookhart, C. Crivera, 2015, International journal of clinical practice.

Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low‐Risk Patients with Pulmonary Embolism

J. Schein, W. Peacock, C. Coleman, 2016, Pharmacotherapy.

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study*

S. Mody, J. Schein, A. Fisher, 2009 .

External validation of the In‐hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) multivariable prediction rule

C. Coleman, G. Fermann, W. F. Peacock, 2016, International journal of clinical practice.

Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel

W. Olson, P. Lefebvre, F. Laliberté, 2014, Journal of clinical pharmacy and therapeutics.

Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies

J. Schein, P. Wells, C. Baugh, 2017, Current medical research and opinion.

Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

J. Schein, C. Coleman, E. Mearns, 2014, Thrombosis Journal.

Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies

C. Baugh, C. Coleman, G. Fermann, 2017, Current medical research and opinion.